Related Experiment Video

Updated: Feb 3, 2026

Dry Oxidation and Vacuum Annealing Treatments for Tuning the Wetting Properties of Carbon Nanotube Arrays
08:59

Dry Oxidation and Vacuum Annealing Treatments for Tuning the Wetting Properties of Carbon Nanotube Arrays

Published on: April 15, 2013

15.4K

[Update from France Macula Federation: Treatment of Wet AMD]

S Tick1, P-L Cornut2, F De Bats3

  • 1Centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75012 Paris, France; Centre ophtalmologique Vincennes, 17, bis rue des Meuniers, 94300 Vincennes, France.

Journal Francais D'Ophtalmologie
|October 27, 2018
PubMed
Abstract

Insights

The France Macula Federation (FFM) updated its wet age-related macular degeneration (AMD) treatment guidelines, recommending prompt anti-VEGF therapy. While intravitreal injection techniques are stable, strategy choice and patient communication are key.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Medical Guidelines

Background:

  • Wet age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Current treatments focus on inhibiting vascular endothelial growth factor (VEGF).

Purpose of the Study:

  • To update the France Macula Federation (FFM) recommendations for managing exudative (wet) AMD.
  • To provide current guidance on anti-VEGF therapy for wet AMD.

Main Methods:

  • Literature analysis
  • Expert opinion synthesis

Main Results:

  • FFM recommends initiating anti-VEGF therapy promptly after wet AMD diagnosis.
  • Intravitreal injection procedures remain largely unchanged.
  • Discussion includes simultaneous bilateral injections, antibiotic use, and medico-legal considerations.
  • Various anti-VEGF strategies exist with distinct advantages and limitations.

Conclusions:

  • Wet AMD treatment is more codified but allows for diverse strategies.
  • Ophthalmologist preference should guide strategy selection, with clear patient communication and adherence.
Keywords:
AfliberceptAnti-VEGFBevacizumabDMLA exsudativeRanibizumabWet AMD

More Related Videos

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.3K
Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion06:15

Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion

Published on: August 15, 2016

8.2K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
997
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
952
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K